Last checked at 4 Oct 2019 08:39
Hutchison China Doses First Patient In HMPL-523 Lymphoma Study
Hutchison China Doses First Patient In HMPL-523 Lymphoma Study
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hutchmed Share News (HCM)
HCM Share
Price
HCM Share
News
HCM Share
Chat
HCM Share
Trades53
HCM
Live RNS
HCM Share
Charts
HCM Level 2
Console
HCM Live
Share Price
HCM Broker
Ratings
HCM Directors
Deals
HCM Financial
Diary
HCM
Fundamentals
HCM Short
Positions
HCM
Media
Hutchmed Information
Share Price Information for Hutchmed (HCM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
300.00
Bid:
299.00
Ask:
300.00
Change:
2.50 (0.84%)
Spread:
1.00 (0.334%)
Open:
292.00
High:
303.00
Low:
292.00
Prev. Close:
297.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.3 Sep 2019 13:25
Hutchison China Starts Trial For HMPL-689 On Lymphoma Treatment
(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at
Read more23 Aug 2019 11:25
Hutchison China MediTech launches trial for autoimmune disorder treatment
(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.
Read more23 Aug 2019 10:59
Hutchison China Meditech Starts HMPL-523 Trial In China
(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last
Read more30 Jul 2019 11:43
Hutchison China Interim Loss Widens On Expenses; Alters 2019 Guidance
(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares
Read more23 Jul 2019 16:01
UK Earnings, Trading Statements Calendar - Next 7 Days
Wednesday 24 July Tullow OilHalf Year ResultsPaypointQ1 Year ResultsLaw
Read more3 Jul 2019 13:42
Prudential Holds 5% Hutchison China Meditech Stake After Deal
(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in
Read more28 Jun 2019 16:38
Hutchison China Meditech Confirms Discounted Nasdaq Offer Pricing
(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also
Read more14 Jun 2019 14:40
Hutchison Chi-Med makes progress with surufatinib
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.
Read more29 May 2019 12:38
Hutchison China Meditech Shareholders Approve Subdivision Of Shares (ALLISS)
LONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a
Read more17 Apr 2019 16:02
UK Shareholder Meetings Calendar - Next 7 Days
Thursday 18 AprilDomino's Pizza GroupSEGRORPC Group (re acquisition by Berry 19 events 22 events 23
Read more3 Apr 2019 12:58
Gama Aviation Appoints Managing Director Of Major Shareholder As Chair
LONDON (Alliance News) - Gama Aviation PLC on Wednesday said it has selected the managing director of major shareholder Hutchison Whampoa China Ltd as its new chair.Shares in business firm
Read more29 Mar 2019 09:16
Hutchison China MediTech Surufatinib Cancer Study Doses First Patient
LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract biliary tract by
Read more11 Mar 2019 11:54
Hutchison loss widens as China legislation hampers revenue
(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.
Read more11 Mar 2019 08:45
Hutchison China Meditech 2018 Loss Widens On New Government Policy
LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to
Read more